查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球單株抗體市場：依生產方法、適應症、原產地、給藥途徑、通路、最終用戶、地區、機會、預測，2017-2031
市場調查報告書
商品編碼
1422081

全球單株抗體市場：依生產方法、適應症、原產地、給藥途徑、通路、最終用戶、地區、機會、預測，2017-2031

Monoclonal Antibodies Market Assessment, By Production Methods, By Indication, By Source, By Route of Administration, By Distribution Channel, By End-users, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5個工作天內

價格

2023年全球單株抗體市場規模為2,164億美元，預計到2031年將達到5,548.4億美元，2024-2031年預測期內複合年增長率為12.49%，預計此情況將會發生。全球單株抗體市場的擴張歸因於生物技術研究的增加、慢性病的流行、技術進步、廣泛的治療應用以及個人化醫療需求的增加。此外，新型單株抗體療法的核准和療效在推動全球單株抗體市場的成長中發揮重要作用。

全球單株抗體市場的顯著成長主要歸因於各種關鍵因素。首先，對生物技術研究的重視和投資的增加顯著推動了上升趨勢。不斷擴大的研究環境促進了基於單株抗體的突破性療法的創造，為新的治療方法鋪平了道路。此外，世界上越來越多的慢性病需要準確有效的治療。單株抗體以其針對致病因子的精確性而聞名，並已成為治療多種慢性疾病的有前途的解決方案。此外，透過改進生產流程並提高單株抗體治療的可及性和有效性，技術進步在全球單株抗體市場中發揮關鍵作用。

單株抗體在非傳統醫療領域的擴大使用進一步推動了全球單株抗體市場的擴張。單株抗已應用於腫瘤學、自體免疫疾病和傳染病等多個領域，使其在解決各種健康問題方面越來越重要。全球單株抗體市場受到個人化醫療需求不斷增長的影響，對個別疾病反應的深入了解加速了單株抗體的採用。單株抗體對特定分子標靶的適應性與個人化醫療方法無縫契合，凸顯了它們在現代醫學中的重要性。此外，對新單株抗體療法的支持和經過驗證的療效將加強我們的市場地位，並為醫療保健提供者和患者提供更大的信心。這證實了其在推動全球單株抗體市場持續擴張中所扮演的關鍵角色。

本報告調查了全球單株抗體市場，並按生產方法、適應症、原產地、給藥途徑、分銷管道、最終用戶、地區和市場參與者提供市場概況，並提供公司簡介等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章 2017-2031年全球單株抗體市場展望

  • 市場規模及預測
  • 按生產方式分
  • 按指示
  • 按產地
  • 按給藥途徑
  • 按分銷渠道
  • 按最終用戶
  • 按地區
  • 按公司劃分的市佔率 (%)，2023 年

第 5 章 2017-2031 年全球單株抗體市場前景（按地區）

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章 市場測繪，2023 年

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

第九章 監理架構與創新

第十章 主要與企業狀況

第11章價格分析

第十二章案例研究

第十三章 主要公司展望

  • Novartis AG
  • GSK plc
  • EpiVax, Inc.
  • Genentech, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Co
  • Pfizer Inc.
  • AstraZeneca plc
  • Eli Lilly And Co
  • Boehringer Ingelheim International GmbH
  • ImmunityBio, Inc.
  • Annexon, Inc.

第十四章 戰略建議

第十五章 查詢及免責聲明

Product Code: MX10946

Global monoclonal antibodies market size was valued at USD 216.4 billion in 2023, which is expected to reach USD 554.84 billion in 2031, with a CAGR of 12.49% for the forecast period between 2024 and 2031F. The expansion of the global monoclonal antibodies market stems from augmented biotechnology research, escalating chronic disease prevalence, advancements in technology, broader therapeutic applications, and an increasing desire for personalized medicine. Moreover, the approval and efficacy of novel monoclonal antibody-based therapies play a substantial role in driving the growth of the global monoclonal antibodies market.

The substantial growth of the global monoclonal antibodies market derives primarily from various pivotal elements. Initially, the increasing emphasis and investment in biotechnology research have notably fueled an upward trend. The expanded research environment has nurtured the creation of groundbreaking therapies based on monoclonal antibodies, opening pathways for fresh treatment approaches. Moreover, the increasing worldwide incidence of chronic diseases necessitates precise and effective treatments. Monoclonal antibodies, known for their precision in targeting disease agents, have emerged as promising solutions for managing diverse chronic conditions. Additionally, technological advancements have played a crucial role by refining production processes and augmenting the accessibility and effectiveness of monoclonal antibody treatments in the global monoclonal antibodies market.

Expanding use of monoclonal antibodies into non-traditional medical domains has further propelled expansion of the global monoclonal antibodies market. Their application now spans across various fields such as oncology, autoimmune disorders, infectious diseases, and more, amplifying their relevance in addressing a broad spectrum of health concerns. The global monoclonal antibodies market is influenced by the rising demand for personalized medicine, fueled by a deeper comprehension of individual disease responses, accelerating the adoption of monoclonal antibodies. Their adaptability to specific molecular targets aligns seamlessly with the personalized healthcare approach, underscoring their significance in modern medical practices. Furthermore, the endorsement and proven effectiveness of new monoclonal antibody therapies reinforce their market standing, instilling greater confidence among healthcare providers and patients alike. It solidifies their pivotal role in continually propelling the ongoing expansion of the global monoclonal antibodies market.

Escalating Chronic Disease Prevalence

The growing prevalence of chronic illnesses acts as a major driver fuelling the expansion of global monoclonal antibodies market. Roughly one in three persons worldwide deal with several chronic illnesses. In the United States, four out of ten persons have two or more chronic diseases, and six out of ten adults have one or more. With chronic conditions impacting a larger population worldwide, there is an increased demand for precise and efficient therapeutic remedies.

Monoclonal antibodies are commended for accurately pinpointing specific disease-causing elements that have become fundamental in managing various chronic health issues. Their capability to precisely identify and counteract these elements position them as a promising avenue for addressing ailments such as cancer, autoimmune disorders, and persistent infections. As complexities of the molecular intricacies behind chronic diseases advance, monoclonal antibodies provide customized treatments, addressing the intricacies of individual patient responses. This synchronization between the requirement for accurate, targeted treatments and the adaptability of monoclonal antibodies significantly elevates their importance in tackling the surge of chronic diseases, thereby fostering the growth of the global monoclonal antibodies market.

Technological Advancements

Advances in technology within monoclonal antibody development and manufacturing have transformed the global monoclonal antibodies market. Various platforms have arisen, refining manufacturing procedures and boosting effectiveness. Breakthroughs such as recombinant DNA technology and high-throughput screening accelerated antibody discovery and production. Moreover, enhancements in bioreactor design and purification methods optimize production, guaranteeing increased yields and purity levels. These technological leaps accelerate antibody development and enhance cost-efficiency and scalability, satisfying the rising need for these treatments. Thus, these advancements significantly drive the rapid expansion of the global monoclonal antibodies market., SUREmAb is an offering launched in September 2023 by JSR Life Sciences Company KPI Biopharma, Inc., based on the KBI SUREtechnology platform and intended to optimise and economically manufacture monoclonal antibodies (mAbs). It is intended to shorten the time needed for development. Furthermore, SUREmAb is designed to deliver titers of up to 10g/L using a less expensive approach to maximise ROI and optimise operational efficiency.

Government Initiatives

Around the globe, governments are proactively executing diverse initiatives to encourage global monoclonal antibodies market growth. These efforts involve a range of approaches: funding research and development, providing incentives for biotech firms, optimizing regulatory procedures to expedite approvals, and fostering partnerships between academia and industry. Moreover, certain government aid in infrastructure improvements is expected to fortify manufacturing capacities and ensure effective distribution channels. These coordinated governmental actions underscore their acknowledgment of monoclonal antibodies' significance in healthcare, aiming to stimulate advancements, affordability, accessibility, and broader market expansion. As part of Project NextGen, which aims to improve readiness for COVID-19 strains and variants, the U.S. Department of Health, and Human Services (HHS) announced the extension of its public-private partnership with Regeneron Pharmaceuticals, Inc., an American biotechnology company, to develop life-saving monoclonal antibodies in September 2023. The HHS is dedicated to cutting down prescription expenses for every American. In the agreement, Regeneron promised that any new product commercialized in the list price within the United States would match or be lower than the retail price compared to the global markets.

Monoclonal Antibodies for Cancer Treatment

Monoclonal antibodies are integral in cancer treatment, serving as a significant driver for the growth of the global monoclonal antibodies market. Their precision targets cancer cells while preserving healthy ones and reducing adverse effects compared to conventional treatments. Operating through mechanisms like inhibiting cell growth or marking cells for immune elimination, these antibodies demonstrate their effectiveness in approved therapies like trastuzumab in breast cancer or rituximab in lymphoma. Ongoing research exploration synergizes them with other treatments for amplified results. Their triumph in cancer therapy escalates demand, fueling ongoing market growth and presenting hopeful avenues for more precise and potent cancer management.

Manaolana Oncology Inc., a new firm founded to explore and promote antibody-based therapeutics against novel cancer antigens, was unveiled in September 2023 by Panacea Venture and The University of Texas MD Anderson Cancer Centre. To advance promising treatments into clinical trials at MD Anderson, Manaolana Oncology aims to expand on the inventive antibody production capabilities and intellectual property of MD Anderson by conducting research and developing novel monoclonal antibodies (mAbs) and other antibody-based therapies for a range of cancer types.

Dominance of Chimeric Monoclonal Antibody

The global monoclonal antibodies market sees a substantial demand for chimeric antibodies owing to their distinct blend of human and non-human antibody components. The hybrid makeup amplifies their therapeutic value by lessening immune responses and enhancing effectiveness. Widely applied in cancer and autoimmune disorder treatments, these antibodies demonstrate minimal side effects and heightened precision in targeting. The market's keen interest in these antibodies arises from their capacity to deliver superior treatment results, mitigate adverse effects, and elevate patient tolerance.

Consequently, their remarkable demand and prominence persist in the global monoclonal antibodies sector. Enzene Biosciences released Cetuximab, a biosimilar of the cancer medication Erbitux, in May 2023. A single patient's eight weeks of treatment with cetuximab, a therapeutic chimeric monoclonal antibody, costs over USD 30 thousand. It is used as a targeted therapy for metastatic colorectal cancer (mCRC) and cancer of the head and neck. Cetuximab from Enzene is made using Chinese Hamster Ovary (CHO) cell lines, which produce more human-like glycosylation patterns. As a result, unfavourable effects in clinical trials are much less common in India.

Future Market Scenario

The future of the global monoclonal antibodies market holds considerable promise, attributed to diverse factors. Ongoing research continuously unveils fresh antibody therapies, extending their applications beyond current boundaries. Technological advancements, such as refined manufacturing approaches and inventive antibody designs, drive cost-effectiveness and bolster therapeutic efficiency. Moreover, the rising worldwide prevalence of chronic ailments perpetuates the demand for precise, personalized treatments, an area where monoclonal antibodies demonstrate significant potential. Government support through funding and streamlined regulations further accelerates market growth. Additionally, the market's adoption of advanced antibody structures, including chimeric varieties, underscores the persistent pursuit of improved patient outcomes. The combination of factors establishes a platform for substantial growth in the global monoclonal antibodies market, promising enhanced innovation, expanded applications, increased accessibility, and heightened effectiveness in managing diverse health conditions.

Key Players Landscape and Outlook

Multiple companies in global monoclonal antibodies market are actively seeking collaborative alliances. These partnerships facilitate the consolidation of knowledge, resources, and technologies, fostering innovation and expediting research and development endeavors. Often, these collaborations entail biotech entities partnering with pharmaceutical leaders, academia, or research bodies to leverage combined strengths in discovering new therapies or refining the current ones.

Through joint ventures, licensing pacts, and research collaborations, there is a mutual exchange of expertise and capabilities, aiming to bolster product pipelines, hasten regulatory approvals, and broaden market presence. The concerted effort ensures a more robust competitive advantage amid the dynamic realm of monoclonal antibody therapies.

A biotech business Icosagen and the Swedish company Salipro Biotech signed a multi-target antibody research partnership in October 2023. According to a statement released on October 10, the agreement made use of Salipro's exclusive platform technology for membrane proteins to find medications that specifically target G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters. These membrane proteins are involved in autoimmune disorders and cancer, among other things.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Monoclonal Antibodies Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Production Methods
    • 4.2.1. In Vivo
    • 4.2.2. In Vitro
  • 4.3. By Indication
    • 4.3.1. Disease Treatment
      • 4.3.1.1. Cancer
      • 4.3.1.2. Organ Transplant Rejection
      • 4.3.1.3. Inflammatory and Autoimmune Disorders
      • 4.3.1.4. Infections
      • 4.3.1.5. Osteoporosis
      • 4.3.1.6. Others
    • 4.3.2. Diagnosis
    • 4.3.3. Research
  • 4.4. By Source
    • 4.4.1. Chimeric
    • 4.4.2. Human
    • 4.4.3. Murine
    • 4.4.4. Humanized
    • 4.4.5. Others
  • 4.5. By Route of Administration
    • 4.5.1. Oral
    • 4.5.2. Intravenous
    • 4.5.3. Subcutaneous
    • 4.5.4. Intramuscular
    • 4.5.5. Intravitreal
    • 4.5.6. Others
  • 4.6. By Distribution Channel
    • 4.6.1. Hospital Pharmacy
    • 4.6.2. Retail Pharmacy
    • 4.6.3. Online Pharmacy
    • 4.6.4. Others
  • 4.7. By End-users
    • 4.7.1. Hospitals
    • 4.7.2. Specialty Clinics
    • 4.7.3. Homecare
    • 4.7.4. Others
  • 4.8. By Region
    • 4.8.1. North America
    • 4.8.2. Europe
    • 4.8.3. South America
    • 4.8.4. Asia-Pacific
    • 4.8.5. Middle East and Africa
  • 4.9. By Company Market Share (%), 2023

5. Global Monoclonal Antibodies Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Production Methods
      • 5.1.2.1. In Vivo
      • 5.1.2.2. In Vitro
    • 5.1.3. By Indication
      • 5.1.3.1. Disease Treatment
      • 5.1.3.1.1. Cancer
      • 5.1.3.1.2. Organ Transplant Rejection
      • 5.1.3.1.3. Inflammatory and Autoimmune Disorders
      • 5.1.3.1.4. Infections
      • 5.1.3.1.5. Osteoporosis
      • 5.1.3.1.6. Others
      • 5.1.3.2. Diagnosis
      • 5.1.3.3. Research
    • 5.1.4. By Source
      • 5.1.4.1. Chimeric
      • 5.1.4.2. Human
      • 5.1.4.3. Murine
      • 5.1.4.4. Humanized
      • 5.1.4.5. Others
    • 5.1.5. By Route of Administration
      • 5.1.5.1. Oral
      • 5.1.5.2. Intravenous
      • 5.1.5.3. Subcutaneous
      • 5.1.5.4. Intramuscular
      • 5.1.5.5. Intravitreal
      • 5.1.5.6. Others
    • 5.1.6. By Distribution Channel
      • 5.1.6.1. Hospital Pharmacy
      • 5.1.6.2. Retail Pharmacy
      • 5.1.6.3. Online Pharmacy
      • 5.1.6.4. Others
    • 5.1.7. By End-users
      • 5.1.7.1. Hospitals
      • 5.1.7.2. Specialty Clinics
      • 5.1.7.3. Homecare
      • 5.1.7.4. Others
    • 5.1.8. United States*
      • 5.1.8.1. By Production Methods
      • 5.1.8.1.1. In Vivo
      • 5.1.8.1.2. In Vitro
      • 5.1.8.2. By Indication
      • 5.1.8.2.1. Disease Treatment
      • 5.1.8.2.1.1. Cancer
      • 5.1.8.2.1.2. Organ Transplant Rejection
      • 5.1.8.2.1.3. Inflammatory and Autoimmune Disorders
      • 5.1.8.2.1.4. Infections
      • 5.1.8.2.1.5. Osteoporosis
      • 5.1.8.2.1.6. Others
      • 5.1.8.2.2. Diagnosis
      • 5.1.8.2.3. Research
      • 5.1.8.3. By Source
      • 5.1.8.3.1. Chimeric
      • 5.1.8.3.2. Human
      • 5.1.8.3.3. Murine
      • 5.1.8.3.4. Humanized
      • 5.1.8.3.5. Others
      • 5.1.8.4. By Route of Administration
      • 5.1.8.4.1. Oral
      • 5.1.8.4.2. Intravenous
      • 5.1.8.4.3. Subcutaneous
      • 5.1.8.4.4. Intramuscular
      • 5.1.8.4.5. Intravitreal
      • 5.1.8.4.6. Others
      • 5.1.8.5. By Distribution Channel
      • 5.1.8.5.1. Hospital Pharmacy
      • 5.1.8.5.2. Retail Pharmacy
      • 5.1.8.5.3. Online Pharmacy
      • 5.1.8.5.4. Others
      • 5.1.8.6. By End-users
      • 5.1.8.6.1. Hospitals
      • 5.1.8.6.2. Specialty Clinics
      • 5.1.8.6.3. Homecare
      • 5.1.8.6.4. Others
    • 5.1.9. Canada
    • 5.1.10. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Production Methods
  • 6.2. By Indication
  • 6.3. By Source
  • 6.4. By Route of Administration
  • 6.5. By Distribution Channel
  • 6.6. By End-users
  • 6.7. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. GSK plc
  • 13.3. EpiVax, Inc.
  • 13.4. Genentech, Inc.
  • 13.5. Amgen Inc.
  • 13.6. Bristol-Myers Squibb Co
  • 13.7. Pfizer Inc.
  • 13.8. AstraZeneca plc
  • 13.9. Eli Lilly And Co
  • 13.10. Boehringer Ingelheim International GmbH
  • 13.11. ImmunityBio, Inc.
  • 13.12. Annexon, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 3. Global Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 4. Global Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 5. Global Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 6. Global Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 7. Global Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Global Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 9. Global Monoclonal Antibodies Market Share (%), By Region, 2017-2031F
  • Figure 10. North America Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 11. North America Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 12. North America Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 13. North America Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 14. North America Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 15. North America Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 16. North America Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 17. North America Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 18. North America Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
  • Figure 19. United States Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. United States Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 21. United States Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 22. United States Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 23. United States Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 24. United States Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 25. United States Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 26. United States Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 27. Canada Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Canada Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 29. Canada Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 30. Canada Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 31. Canada Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 32. Canada Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 33. Canada Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 34. Canada Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 35. Mexico Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 36. Mexico Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 37. Mexico Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 38. Mexico Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 39. Mexico Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 40. Mexico Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 41. Mexico Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 42. Mexico Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 43. Europe Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Europe Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 45. Europe Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 46. Europe Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 47. Europe Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 48. Europe Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 49. Europe Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 50. Europe Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 51. Europe Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
  • Figure 52. Germany Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Germany Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 54. Germany Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 55. Germany Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 56. Germany Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 57. Germany Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. Germany Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Germany Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 60. France Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. France Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 62. France Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 63. France Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 64. France Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 65. France Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 66. France Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67. France Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 68. Italy Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 69. Italy Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 70. Italy Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 71. Italy Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 72. Italy Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 73. Italy Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74. Italy Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 75. Italy Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 76. United Kingdom Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. United Kingdom Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 78. United Kingdom Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 79. United Kingdom Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 80. United Kingdom Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 81. United Kingdom Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 82. United Kingdom Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 83. United Kingdom Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 84. Russia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Russia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 86. Russia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 87. Russia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 88. Russia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 89. Russia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 90. Russia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 91.
  • Figure 92. Russia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 93. Netherlands Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 94. Netherlands Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 95. Netherlands Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 96. Netherlands Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 97. Netherlands Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 98. Netherlands Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. Netherlands Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. Netherlands Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 101. Spain Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Spain Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 103. Spain Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 104. Spain Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 105. Spain Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 106. Spain Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 107. Spain Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 108. Spain Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 109. Turkey Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. Turkey Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 111. Turkey Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 112. Turkey Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 113. Turkey Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 114. Turkey Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. Turkey Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. Turkey Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 117. Poland Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Poland Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 119. Poland Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 120. Poland Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 121. Poland Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 122. Poland Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 123. Poland Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124. Poland Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 125. South America Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 126. South America Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 127. South America Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 128. South America Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 129. South America Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 130. South America Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. South America Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. South America Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 133. South America Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
  • Figure 134. Brazil Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 135. Brazil Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 136. Brazil Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 137. Brazil Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 138. Brazil Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 139. Brazil Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140. Brazil Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141. Brazil Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 142. Argentina Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 143. Argentina Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 144. Argentina Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 145. Argentina Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 146. Argentina Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 147. Argentina Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 148. Argentina Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 149. Argentina Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 150. Asia-Pacific Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. Asia-Pacific Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 152. Asia-Pacific Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 153. Asia-Pacific Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 154. Asia-Pacific Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 155. Asia-Pacific Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156. Asia-Pacific Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157. Asia-Pacific Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 158. Asia-Pacific Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
  • Figure 159. India Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 160. India Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 161. India Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 162. India Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 163. India Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 164. India Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 165. India Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 166. India Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 167. China Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. China Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 169. China Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 170. China Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 171. China Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 172. China Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. China Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. China Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 175. Japan Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Japan Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 177. Japan Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 178. Japan Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 179. Japan Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 180. Japan Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 181. Japan Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 182. Japan Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 183. Australia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 184. Australia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 185. Australia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 186. Australia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 187. Australia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 188. Australia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 189. Australia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 190. Australia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 191. Vietnam Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 192. Vietnam Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 193. Vietnam Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 194. Vietnam Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 195. Vietnam Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 196. Vietnam Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 197. Vietnam Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 198. Vietnam Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 199. South Korea Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 200. South Korea Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 201. South Korea Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 202. South Korea Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 203. South Korea Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 204. South Korea Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 205. South Korea Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 206. South Korea Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 207. Indonesia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 208. Indonesia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 209. Indonesia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 210. Indonesia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 211. Indonesia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 212. Indonesia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 213. Indonesia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 214. Indonesia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 215. Philippines Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 216. Philippines Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 217. Philippines Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 218. Philippines Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 219. Philippines Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 220. Philippines Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 221. Philippines Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 222. Philippines Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 223. Middle East & Africa Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 224. Middle East & Africa Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 225. Middle East & Africa Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 226. Middle East & Africa Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 227. Middle East & Africa Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 228. Middle East & Africa Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 229. Middle East & Africa Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 230. Middle East & Africa Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 231. Middle East & Africa Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
  • Figure 232. Saudi Arabia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 233. Saudi Arabia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 234. Saudi Arabia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 235. Saudi Arabia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 236. Saudi Arabia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 237. Saudi Arabia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 238. Saudi Arabia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 239. Saudi Arabia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 240. UAE Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. UAE Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 242. UAE Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 243. UAE Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 244. UAE Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 245. UAE Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 246. UAE Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 247. UAE Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 248. South Africa Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
  • Figure 249. South Africa Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
  • Figure 250. South Africa Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
  • Figure 251. South Africa Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
  • Figure 252. South Africa Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
  • Figure 253. South Africa Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
  • Figure 254. South Africa Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 255. South Africa Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
  • Figure 256. By Production Methods Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 257. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 258. By Source Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 259. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 260. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 261. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023